143 related articles for article (PubMed ID: 12867493)
1. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition.
Neal JM; Kunze KL; Levy RH; O'Reilly RA; Trager WF
Drug Metab Dispos; 2003 Aug; 31(8):1043-8. PubMed ID: 12867493
[TBL] [Abstract][Full Text] [Related]
2. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies.
Black DJ; Kunze KL; Wienkers LC; Gidal BE; Seaton TL; McDonnell ND; Evans JS; Bauwens JE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):422-8. PubMed ID: 8801057
[TBL] [Abstract][Full Text] [Related]
3. Potentiation of anticoagulant effect of warfarin caused by enantioselective metabolic inhibition by the uricosuric agent benzbromarone.
Takahashi H; Sato T; Shimoyama Y; Shioda N; Shimizu T; Kubo S; Tamura N; Tainaka H; Yasumori T; Echizen H
Clin Pharmacol Ther; 1999 Dec; 66(6):569-81. PubMed ID: 10613612
[TBL] [Abstract][Full Text] [Related]
4. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies.
Kunze KL; Wienkers LC; Thummel KE; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):414-21. PubMed ID: 8801056
[TBL] [Abstract][Full Text] [Related]
5. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction.
Kunze KL; Trager WF
Drug Metab Dispos; 1996 Apr; 24(4):429-35. PubMed ID: 8801058
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic interaction between warfarin and a uricosuric agent, bucolome: application of In vitro approaches to predicting In vivo reduction of (S)-warfarin clearance.
Takahashi H; Kashima T; Kimura S; Murata N; Takaba T; Iwade K; Abe T; Tainaka H; Yasumori T; Echizen aH
Drug Metab Dispos; 1999 Oct; 27(10):1179-86. PubMed ID: 10497145
[TBL] [Abstract][Full Text] [Related]
7. Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children.
Takahashi H; Ishikawa S; Nomoto S; Nishigaki Y; Ando F; Kashima T; Kimura S; Kanamori M; Echizen H
Clin Pharmacol Ther; 2000 Nov; 68(5):541-55. PubMed ID: 11103757
[TBL] [Abstract][Full Text] [Related]
8. Significant pharmacokinetic and pharmacodynamic interaction of warfarin with the NO-independent sGC activator HMR1766.
Oberwittler H; Hirschfeld-Warneken A; Wesch R; Willerich H; Teichert L; Lehr KH; Ding R; Haefeli WE; Mikus G
J Clin Pharmacol; 2007 Jan; 47(1):70-7. PubMed ID: 17192504
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and metronidazole in rats.
Yacobi A; Lai CM; Levy G
J Pharmacol Exp Ther; 1984 Oct; 231(1):72-9. PubMed ID: 6491976
[TBL] [Abstract][Full Text] [Related]
10. Limited sampling strategy of S-warfarin concentrations, but not warfarin S/R ratios, accurately predicts S-warfarin AUC during baseline and inhibition in CYP2C9 extensive metabolizers.
Ma JD; Nafziger AN; Kashuba AD; Kim MJ; Gaedigk A; Rowland E; Kim JS; Bertino JS
J Clin Pharmacol; 2004 Jun; 44(6):570-6. PubMed ID: 15145963
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of a potential tigecycline-warfarin drug interaction.
Zimmerman JJ; Raible DG; Harper DM; Matschke K; Speth JL
Pharmacotherapy; 2008 Jul; 28(7):895-905. PubMed ID: 18576904
[TBL] [Abstract][Full Text] [Related]
12. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
[TBL] [Abstract][Full Text] [Related]
13. Selective inhibition of warfarin metabolism by diltiazem in humans.
Abernethy DR; Kaminsky LS; Dickinson TH
J Pharmacol Exp Ther; 1991 Apr; 257(1):411-5. PubMed ID: 2020000
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of (S)-warfarin metabolism by sulfinpyrazone and its metabolites.
He M; Kunze KL; Trager WF
Drug Metab Dispos; 1995 Jun; 23(6):659-63. PubMed ID: 7587949
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic studies of acute interaction between warfarin enantiomers and chloramphenicol in rats.
Yacobi A; Lai CM; Levy G
J Pharmacol Exp Ther; 1984 Oct; 231(1):80-4. PubMed ID: 6491977
[TBL] [Abstract][Full Text] [Related]
16. Prediction of pharmacokinetic drug-drug interactions using human hepatocyte suspension in plasma and cytochrome P450 phenotypic data. III. In vitro-in vivo correlation with fluconazole.
Lu C; Berg C; Prakash SR; Lee FW; Balani SK
Drug Metab Dispos; 2008 Jul; 36(7):1261-6. PubMed ID: 18381488
[TBL] [Abstract][Full Text] [Related]
17. Possible interaction between warfarin and fluconazole.
Gericke KR
Pharmacotherapy; 1993; 13(5):508-9. PubMed ID: 8247921
[TBL] [Abstract][Full Text] [Related]
18. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants.
Bavisotto LM; Ellis DJ; Milner PG; Combs DL; Irwin I; Canafax DM
J Clin Pharmacol; 2011 Apr; 51(4):561-74. PubMed ID: 20622200
[TBL] [Abstract][Full Text] [Related]
19. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone.
Lewis RJ; Trager WF; Chan KK; Breckenridge A; Orme M; Roland M; Schary W
J Clin Invest; 1974 Jun; 53(6):1607-17. PubMed ID: 4830225
[TBL] [Abstract][Full Text] [Related]
20. Absence of a pharmacokinetic interaction between etanercept and warfarin.
Zhou H; Patat A; Parks V; Buckwalter M; Metzger D; Korth-Bradley J
J Clin Pharmacol; 2004 May; 44(5):543-50. PubMed ID: 15102876
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
